Transfemoral Transcatheter Aortic Valve Implementation at Hospital Without On-site Cardiac Surgery: Early Clinical Outcome in Patients With Prohibitive Surgical Risk.

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Study design: single arm, interventional and multicenter study. The objectives are evaluate Safety and efficacy of TAVI in Department of Cardiology without on site cardiac Surgery for symptomatic severe aortic valve stenosis by expert operator team, in patients with prohibitive surgical risk. For the pilot phase, 20 patients will be enrolled. For whole study, all consecutive patients undergoing TAVI in center without CS on site will be enrolled to reach a number of about 200 patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 75
Maximum Age: 120
Healthy Volunteers: f
View:

• Senile degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient \> 40 mmHg or jet velocity \> 4.0 m/s aortic valve area (AVA) of \< 0.8 cm2 (or AVA index \< 0.5 cm2/m2)

• Symptomatic due to aortic valve stenosis as demonstrated by NYHA Functional Class \> = II

• Age \>= 75 years old

• Patients with prohibitive risk established in the Heart Team and defined on the basis of the following clinica instrument criteria according with the Varc-2 consensus.

• High surgical risk (%, logES\>20%, EuroSCORE II \> 9 and STS score \> 8%)

• Porcelain aorta (heavy circumferential calcification or severe atheromatous plaques that do not allow clamping.

• Hostile chest (abnormal chest wall anatomy due to severe kyphoscoliosis or other skeletal abnormalities, complications form to previous surgery, evidence of severe radiotion damege, history of multiple recurrent pleural effusions causing internal adhesions.

• Fragilty (slowness, weakness, exhaustion, wasting and malnutrition, poor endurance and inactivity, loss of independence, BMI \< 20 Kg/m2 and or weight loss 5 kg/year, serum albumin \< 3,5 g/dl, cognitive impairment or dementia)

• Severe liver disease/cirrosis

• Presence of a patent graft of an internal mammary artery crossing mildline and/or adherent to posterior table of sternum

• Severe pulmoary hypertension

• Severe right ventricular dysfunction

• Transfemoral access allowed

• Signature of informed consent

Locations
Other Locations
Italy
Ospedale Generale Regionale F Miulli
RECRUITING
Acquaviva Delle Fonti
AUSL Romagna Morgagni - Pierantoni Hospital
RECRUITING
Forlì
Ospedale Santa Maria della Croci
RECRUITING
Ravenna
Spain
Hospital del Mar
RECRUITING
Barcelona
Contact Information
Primary
Fabio Tarantino, Medical Director
fabio.tarantino@auslromagna.it
0543735132
Backup
Miriam Compagnone
0543735132
Time Frame
Start Date: 2023-05-01
Estimated Completion Date: 2026-04
Participants
Target number of participants: 200
Treatments
Experimental: TAVI procedure
Patients will be evaluated at baseline to access their eligibility for the procedure. The day of TAVI patients will be prepared for the procedures as the institution's standard practice for an invasive percutaneous endovascular procedure. During the pre hospital discharge period, patients will be monitored and will receive standard post-procedure care as judged appropriate by PI. At 30 days from the procedure a Fu visit will be made in order to access survival and adverse clinical events.
Sponsors
Leads: AUSL Romagna Rimini

This content was sourced from clinicaltrials.gov